Campbell Wealth Management Has $207,000 Holdings in Merck & Co., Inc. (NYSE:MRK)

Campbell Wealth Management lowered its stake in Merck & Co., Inc. (NYSE:MRK) by 36.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,824 shares of the company’s stock after selling 1,067 shares during the period. Campbell Wealth Management’s holdings in Merck & Co., Inc. were worth $207,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Industrial Alliance Investment Management Inc. lifted its position in shares of Merck & Co., Inc. by 2.6% in the first quarter. Industrial Alliance Investment Management Inc. now owns 3,193 shares of the company’s stock worth $421,000 after buying an additional 80 shares during the last quarter. IRON Financial LLC lifted its position in shares of Merck & Co., Inc. by 4.6% in the second quarter. IRON Financial LLC now owns 1,811 shares of the company’s stock worth $224,000 after buying an additional 80 shares during the last quarter. Argent Capital Management LLC lifted its position in shares of Merck & Co., Inc. by 0.8% during the 2nd quarter. Argent Capital Management LLC now owns 10,521 shares of the company’s stock worth $1,302,000 after purchasing an additional 81 shares during the last quarter. Forza Wealth Management LLC lifted its position in shares of Merck & Co., Inc. by 0.8% during the 2nd quarter. Forza Wealth Management LLC now owns 10,480 shares of the company’s stock worth $1,297,000 after purchasing an additional 82 shares during the last quarter. Finally, Vista Investment Partners LLC lifted its position in shares of Merck & Co., Inc. by 2.0% during the 2nd quarter. Vista Investment Partners LLC now owns 4,164 shares of the company’s stock worth $516,000 after purchasing an additional 82 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the subject of several research analyst reports. Bank of America cut their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price target on shares of Merck & Co., Inc. in a report on Thursday, October 3rd. Truist Financial cut their price target on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. BMO Capital Markets cut their price target on Merck & Co., Inc. from $150.00 to $136.00 and set an “outperform” rating for the company in a report on Friday. Finally, Citigroup cut their price target on Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating for the company in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.93.

Merck & Co., Inc. Stock Down 0.4 %

Shares of MRK opened at $101.87 on Friday. The firm has a market capitalization of $258.02 billion, a price-to-earnings ratio of 21.36, a PEG ratio of 1.50 and a beta of 0.39. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47. The business’s fifty day moving average price is $112.29 and its two-hundred day moving average price is $120.87. Merck & Co., Inc. has a 52 week low of $98.60 and a 52 week high of $134.63.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. The firm had revenue of $16.66 billion for the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a return on equity of 40.69% and a net margin of 21.99%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company earned $2.13 EPS. On average, analysts predict that Merck & Co., Inc. will post 7.76 earnings per share for the current year.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.